SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabien Tech. Regulatory News (SNT)

Share Price Information for Sabien Tech. (SNT)

Share Price is delayed by 15 minutes
Get Live Data
3.75    0.00 (0.00%)
Bid:
3.50
Ask:
4.00
Spread: 0.50 (14.286%)
Market Cap: £1.04m
SNT Live PriceLast checked at - London Stock Exchange

Intraday Sabien Tech. Share Chart

Warrant Exercise

26 Nov 2021 07:00

RNS Number : 6622T
Sabien Technology Group PLC
26 November 2021
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION 11 OF THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019/310.

26 November 2021

Sabien Technology Group plc

("Sabien" or the "Company")

Warrant Exercise Notice and Total Voting Rights

Sabien Technology Group plc, a company focussed on building a portfolio of operations which, in combination, provide critical elements of the transition to a Green Economy, announces that it has received an exercise notice from investors in relation to 50,000 warrants.

The Company announced the issue of the warrants on 20 January 2021, which are exercisable at an exercise price of 30 pence per share following the 29 March 2021 300:1 share consolidation. Accordingly, pursuant to the warrant exercise notice, Sabien will issue 50,000 new ordinary shares of 3 pence each in the capital of the Company ("Ordinary Shares") (the "New Shares"). Application will be made for the New Shares to be admitted to trading on AIM and admission is expected to become effective on 2 December 2021 ("Admission"). 

Following Admission, the Company will have 14,720,168 Ordinary Shares in issue, each share carrying the right to one vote. The Company does not hold any Ordinary Shares in Treasury. Following Admission, the figure of 14,720,168 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Further Information:

Sabien Technology Group plc

Richard Parris, Executive Chairman

 

+44 20 7993 3700

 

Allenby Capital Limited (Nominated Adviser)

John Depasquale / Nick Harriss / Vivek Bhardwaj

 

+44 20 3328 5656

Peterhouse Capital Limited (Broker)

Duncan Vasey / Lucy Williams

+44 20 7469 0930

 

The person who arranged for the release of this announcement on behalf of the Company was Richard Parris, Executive Chairman.

A copy of this announcement will be available from the Company's website at www.sabien-tech.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEFESFUIEFSELF
Date   Source Headline
9th Jan 20247:00 amRNSTrading Update
29th Nov 20231:00 pmRNSResult of AGM
29th Nov 20237:30 amRNSAGM Statement
21st Nov 20231:30 pmRNSHolding(s) in Company
3rd Nov 20234:50 pmRNSHolding(s) in Company
2nd Nov 20231:34 pmRNSHolding(s) in Company
2nd Nov 20237:00 amRNSFinal Results & Annual Report & Accounts for 2023
1st Nov 20237:15 amRNSUpdate on 2023 Audited Accounts
4th Oct 20237:00 amRNSM2G Rollout in US
26th Sep 20237:00 amRNSProton Technologies
22nd Sep 20236:00 pmRNSHolding(s) in Company
6th Jul 20237:00 amRNSTrading Update
8th Jun 20237:00 amRNSM2G Business Update
16th May 20237:00 amRNSFurther update on b.grn and related matters
17th Apr 20237:00 amRNSUpdate on b.grn
13th Apr 20239:15 amRNSHolding(s) in Company
6th Apr 20237:00 amRNSDirector/PCA Shareholding
5th Apr 20235:00 pmRNSDirector/PDMR Shareholding
31st Mar 20237:00 amRNSInterim Results for the 6 months to 31 Dec 2022
28th Mar 20237:00 amRNSMaterial M2G Order & Business Update
27th Mar 20237:00 amRNSM2G supports Empiric on net zero goals
10th Mar 202311:33 amRNSHolding(s) in Company
10th Mar 202311:30 amRNSHolding(s) in Company
10th Mar 20237:00 amRNSMaterial M2G order and M2G trading update
28th Feb 20232:45 pmRNSHolding(s) in Company
6th Feb 20234:30 pmRNSHolding(s) in Company
2nd Feb 20234:51 pmRNSHolding(s) in Company
22nd Nov 202212:00 pmRNSResult of AGM
22nd Nov 20227:30 amRNSInvestor Update & Annual General Meeting Statement
18th Nov 20221:46 pmRNSHolding(s) in Company
10th Nov 20227:00 amRNSInvestor Update Presentation
2nd Nov 20227:00 amRNSSupply of UK's First Regenerative Green Oil System
24th Oct 20227:00 amRNSOrder Update – New Channel Partner & Customer
17th Oct 20222:47 pmRNSHoling(s) in Company
17th Oct 20221:54 pmRNSHolding(s) in Company
17th Oct 20227:00 amRNSHoling(s) in Company
17th Oct 20227:00 amRNSInternational Environmental Trae Summit Upate
17th Oct 20227:00 amRNSInternational Environmental Trade Summit Update
17th Oct 20227:00 amRNSHolding(s) in Company
14th Oct 20227:00 amRNSFinal Results for the Year to 30 June 2022
12th Oct 20227:00 amRNSHolding(s) in Company
5th Oct 20223:33 pmRNSHolding(s) in Company
23rd Sep 20222:49 pmRNSHolding(s) in Company
20th Sep 20224:16 pmRNSHolding(s) in Company
16th Sep 20227:00 amRNSRevised Date for Summit for S'th Korean Delegation
31st Aug 20225:00 pmRNSTotal Voting Rights
25th Aug 20223:30 pmRNSAdmission to trading of new Ordinary Shares
22nd Aug 20226:24 pmRNSResult of General Meeting
19th Aug 20227:00 amRNSSales Channel Partnership
16th Aug 20227:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.